Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 385 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Menstruation Clear all
Completed No phase listed Observational Accepts healthy volunteers

Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome

NCT03547453
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity, Overweight and Obesity
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of CBD Isolate on Menstrual-Related Symptoms

NCT05679830
View directory record Official record
Conditions
Menstrual Discomfort
Interventions
Cannabidiol
Drug
Lead sponsor
Canopy Growth Corporation
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Harrisonburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
View directory record Official record
Conditions
Endometriosis
Interventions
Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 20, 2026, 5:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Research Study Exploring How Musculoskeletal Function and the Autonomic Nervous System Relate to Visceral Pain in Women With and Without Dysmenorrhea (Painful Periods).

NCT07209566
View directory record Official record
Conditions
Dysmenorrhea, Dysmenorrhea Primary, Visceral Pain, Menstrual Pain
Interventions
Visceral Pain Stimulus
Diagnostic Test
Lead sponsor
Azusa Pacific University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Not applicable Interventional

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

NCT04425577
View directory record Official record
Conditions
Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
Interventions
Transabdominal Ultrasound
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 22 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 20, 2026, 5:45 PM EDT
Not listed No phase listed Observational

Post Approval NovaSure Essure Labeling Study

NCT01934244
View directory record Official record
Conditions
Menorrhagia
Interventions
NovaSure Endometrial Ablation
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Arvada, Colorado • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 20, 2026, 5:45 PM EDT
Recruiting No phase listed Observational

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

NCT07169136
View directory record Official record
Conditions
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Interventions
GLP-1 Receptor Agonists
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

NCT05007899
View directory record Official record
Conditions
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions
Ferrous sulfate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 22 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

NCT00628901
View directory record Official record
Conditions
Leiomyoma, Uterine Fibroids, Uterine Neoplasms, Menorrhagia, Leiomyomatosis
Interventions
Uterine Fibroid Embolization (UFE), Contour SE™ Microspheres, Embosphere® Microspheres
Procedure · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 20, 2026, 5:45 PM EDT
Recruiting Phase 2 Interventional

Acupuncture for People Experiencing Period Loss Due to Chemotherapy

NCT06915116
View directory record Official record
Conditions
Cancer, Period Problem
Interventions
Acupuncture, No Acupuncture
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 5:45 PM EDT
Completed No phase listed Observational

Bone Mineral Density in Women With Uterine Fibroids or Endometriosis

NCT03744507
View directory record Official record
Conditions
Uterine Fibroid, Endometriosis
Interventions
Not listed
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
660 participants
Timeline
2018 – 2020
U.S. locations
37
States / cities
Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tampon Safety-in-Use Study

NCT07561905
View directory record Official record
Conditions
Menstruation
Interventions
Tampon A
Device
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Treatment of Primary Menstrual Pain With Kanion Capsule

NCT00523146
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
Kanion Capsule
Drug
Lead sponsor
Lianyungang Kanion Group, Ltd.
Industry
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Sandy Springs, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Determining How Quickly Progesterone Slows LH Pulse Frequency

NCT00594217
View directory record Official record
Conditions
Normal, PCOS
Interventions
oral micronized progesterone suspension, Placebo
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Sonography Guided Transcervical Ablation of Uterine Fibroids

NCT02228174
View directory record Official record
Conditions
Menorrhagia
Interventions
Intrauterine Ultrasound-Guided Radiofreq. Ablation System
Device
Lead sponsor
Gynesonics
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Not applicable Interventional

Alternative Treatments for Premenstrual Dysphoric Disorder

NCT01799733
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder
Interventions
LWT+AM BWL, EWT+PM BWL
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 20, 2026, 5:45 PM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

NCT03400943
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
52
States / cities
Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 20, 2026, 5:45 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Missed Period Pill Study

NCT04940013
View directory record Official record
Conditions
Menstrual Regulation, Menstrual Irregularity
Interventions
Misoprostol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 20, 2026, 5:45 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

NCT04856306
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Fibroid Uterus
Interventions
Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
Other · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine

NCT00644033
View directory record Official record
Conditions
Menstrually Associated Migraine
Interventions
Frovatriptan, Placebo
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Chadds Ford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03271489
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
155
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Transcutaneous Electrical Nerve Stimulation (TENS) for Menstrual Pain Relief

NCT05178589
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
One Unit TENS, Two Unit TENS
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 20, 2026, 5:45 PM EDT
Active, not recruiting Phase 3 Interventional

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

NCT04333576
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix, Placebo, Combined Oral Contraceptive
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
176
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 20, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204318
View directory record Official record
Conditions
Endometriosis Related Pain
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 20, 2026, 5:45 PM EDT